Targets › PAUF
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Functions as a lectin that binds to selective commensal dental plaque bacteria, such as Streptococcus vestibularis. Contributes to maintain homeostasis in the oral microbiome by capturing commensal microbes and regulating their growth using a mucin-assisted clearance mechanism. (UniProt, Q96DA0)
Open in Phaseline: the race on PAUF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Prestige Biopharma | PBP1510 Anti-PAUF monoclonal antibody | PAUF | Phase 1 | Pancreatic Cancer | Dec 2026 |
Pancreatic Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.